Effect of Exercise on Irisin Levels of Hypothyroid Rats

November 19, 2024 updated by: Riphah International University

The Effect of Exercise on Serum Irisin Levels in Hypothyroid Sprague Dawley Rats

The aim of study was to evaluate the role of exercise on serum irisin levels in hypothyroid rats.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Contracting skeletal muscle acts as an endocrine organ, capable of secreting hormones called myokines, such as interleukin 1, Interleukin 15 and Irisin. Myokines are important for regulation of glucose and lipid metabolism. Among these, irisin, is an exercise induced polypeptide, secreted mainly by skeletal muscles and adipose tissue. Irisin is also secreted in small amounts from cardiac muscle, pancreas and sebaceous glands. It is cleaved and secreted from fibronectin type III domain-containing protein 5 (FNDC5 gene) and is regulated by the peroxisome proliferator-activated receptor-γ co activator 1-α (PGC1-α) .

The most important function of Irisin is thermogenesis, by inducing the browning of white adipose tissue, thereby increasing energy consumption, encouraging weight loss and decreasing dietary insulin resistance. Linking Irisin levels with obesity, its mechanism shows that after exercise there is up regulation of a thermogenin ,an Uncoupling Protein-1 (UCP-1) Thyroid hormone also plays an important role in glucose-lipid metabolism and energy homeostasis. Hypothyroidism, a decrease in thyroid hormone levels, can lead to obesity and metabolic syndrome. It has been found that thyroid hormone is also involved in thermogenesis by inducing browning of white adipose tissue, through thyroid hormone receptors. In hypothyroidism, many metabolic processes in the body are affected such as differentiation in the adipose tissue. Increased thyroid stimulating hormone (TSH) causes adipogenesis by stimulating pre-adipocyte differentiation directly through the receptors in the adipose tissue . Fatty tissue is increased by adipocyte hypertrophy as a consequence of previous adipogenesis, and newly formed adipocyte-8, resulting in clinical obesity.

FNDC5 (Fibronectin type III domain-containing protein 5), which is the precursor of irisin, is a protein that is encoded by the FNDC5 gene, is present in many tissues, including the thyroid tissue and therefore effects thyroid hormone.

Dysregulation of both Thyroid and Irisin hormones result in metabolic syndrome. The metabolic syndrome is a common metabolic disorder that has been linked to the increasing prevalence of obesity. By regulating thyroid hormone levels, irisin has a powerful impact on metabolism and thermogenesis. The association of irisin with the thyroid hormone in hypothyroidism still remains unknown and is controversial, and requires further confirmatory studies on experimental models.

Regular exercise is known to have significant beneficial effects on the metabolic health and this is mediated by skeletal muscle. Contracting skeletal muscle is the source of Irisin. Studies have shown an increase in post exercise Irisin levels

Study Type

Interventional

Enrollment (Actual)

30

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Pakistan
    • Federal
      • Islamabad, Federal, Pakistan, 44000
        • National Institute Of Health

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Child

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

  • Male adult rats weighing approx. 200-250gms
  • 6 to 8 week old rats

Exclusion Criteria:

  • Female rats will be excluded.
  • Rats with any obvious pathology
  • The rats weighing >200gm

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Group I (Control or Euthyroid) total number of rats=20
Fed on normal standard diet
Other: Control or Euthyroid group
Fed on normal standard diet
Experimental: Group II (Hypothyroid) total number of rats=20
Experimental hypothyroidism will be induced by administration of propylthiouracil for three weeks in the form of tablets diluted in water
Other: Hypothyroid group
Experimental hypothyroidism will be induced by administration of propylthiouracil for three weeks in the form of tablets diluted in water
Experimental: Group III (Hypothyroid received exercise) total number of rats=20
Rats will be subjected to chronic swimming. The swimming protocol will consist of 8 weeks of low-intensity swimming exercise.
Other: Hypothyroid group received exercise
Rats will be subjected to chronic swimming. The swimming protocol will consist of 8 weeks of low-intensity swimming exercise. The exercise groups will be adapted to a round water tank (70 cm × 70 cm) containing water at 28 ± 2°C for 3 days (10-45 min/day). The rats will then begin swimming, 45 min/day for the first two weeks at 10am and 60 min/day for the last six weeks at 10am

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Serum Triiodothyronine T3
Time Frame: 11th week
Estimation of serum free triiodothyronine (FT3) levels (ng/ml) by radioimmunoassay
11th week
Serum Thyroxine
Time Frame: 11th week
Estimation of serum free thyroxin (FT4) levels (μg/dl) by radioimmunoassay
11th week
Serum Irisin
Time Frame: 11th week
Estimation of serum irisin levels (μg/ml) by using enzyme - linked immunosorbent assay (ELISA) using irisin competitive ELISA Kit
11th week
Serum Thyroid Stimulating Hormone
Time Frame: 11th week
By radioimmunoassay
11th week
Serum Triglycerides (TG)
Time Frame: 11th week
By enzymatic method using micro lab analyzer
11th week
Serum High Density Lipoproteins (HDL)
Time Frame: 11th week
Determined by precipitating method using micro lab analyzer
11th week
Serum Low Density Lipoproteins (LDL)
Time Frame: 11th week
LDL= Total cholesterol-HDL-TG/5
11th week

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Riphah International University

Investigators

  • Principal Investigator: Shazia Ali, PhD, Riphah International University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

February 20, 2021

Primary Completion (Actual)

January 30, 2022

Study Completion (Actual)

January 30, 2022

Study Registration Dates

First Submitted

February 2, 2021

First Submitted That Met QC Criteria

November 19, 2024

First Posted (Estimated)

November 21, 2024

Study Record Updates

Last Update Posted (Estimated)

November 21, 2024

Last Update Submitted That Met QC Criteria

November 19, 2024

Last Verified

November 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • IRC/20/232 Fatima Iqbal

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypothyroidism

Clinical Trials on Control or Euthyroid group

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Egypt

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe